Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FASgen Inc.

Latest From FASgen Inc.

Start-Up Previews (6/02)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Gene Delivery, features profiles of ImaRx Therapeutics Inc., Intradigm Corp., Protiva Biotherapeutics Inc. and Tranzyme Inc. Plus these Selected Start-Ups across Health Care: FASgen Inc., Power Medical Interventions Inc., NephRx Corp. and Tessera Diagnostics Inc.


The serendipitous discovery of fatty acid synthetase (FAS) in tumor biopsies led a team of Johns Hopkins University researchers to start studying the role of FAS in cancer. Some 15 years after this discovery, the researchers founded FASgen Inc. to develop small molecule FAS inhibitors for cancer, obesity, and tuberculosis.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • FASgen Inc.
  • Senior Management
  • Albert Owens, Jr., MD, CEO
    Francis P Kuhajda, MD, CSO
  • Contact Info
  • FASgen Inc.
    Phone: (410) 558-9200
    Johns Hopkins Bayview Campus Alpha Ctr.
    5210 Eastern Av
    Baltimore, MD 21224